SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: As different studies described different features of the diseases like different JAK/STAT mutations in CTCL patients [32,33,34], the results of some in vitro and clinical studies showed that CTCL patients may benefit from treatment with JAK inhibitors or show the reversal of side effects [22,35,36,37].